Do I need a referral to see a doctor about medicinal cannabis?

Not strictly — any registered medical practitioner can apply through the TGA's Special Access Scheme Category B on a patient's behalf, and some clinics operate as general practice. However, many GPs will refer to a specialist for complex cases, and some states require specialist involvement for certain Schedule 8 applications. Check with your GP as a first step.

Will my private health insurer cover medicinal cannabis?

Generally no. Most medicinal cannabis products in Australia are unapproved therapeutic goods accessed through SAS-B or the Authorised Prescriber pathway, and private health insurers do not typically cover unapproved medicines. Some pharmaceutical-grade products with full ARTG registration may be treated differently, but this varies by insurer and policy. Confirm directly with your fund.

Is medicinal cannabis on the Pharmaceutical Benefits Scheme (PBS)?

As of this writing, no medicinal cannabis product is listed on the PBS, meaning patients pay full out-of-pocket costs. This has been raised as an equity concern in parliamentary submissions and public health commentary, but no PBS listing has been approved. The TGA and PBS are separate processes — ARTG registration does not automatically trigger PBS listing.

What's the difference between the SAS and the Authorised Prescriber pathway?

Under the Special Access Scheme (SAS-B), a doctor applies to the TGA individually for each patient before prescribing an unapproved product. Under the Authorised Prescriber (AP) pathway, a doctor applies once — with ethics committee or specialist college endorsement — to be authorised to prescribe a specific product to a defined class of patients without needing individual TGA approval each time. AP status reduces administrative burden for prescribers who regularly treat patients in a particular area.

Can THC-containing products be prescribed for any condition, or only specific ones?

The SAS-B pathway does not restrict prescribing to a fixed list of approved indications — a doctor can apply for any patient for whom they consider it clinically appropriate. However, the TGA evaluates each application and may decline. Under the Authorised Prescriber pathway, the authorisation is tied to a specific patient population or condition. The clinical evidence base varies considerably across different conditions, and TGA guidance documents outline the strength of evidence the regulator has reviewed.

Medicinal Cannabis Access in Australia: FAQ

By Tom Whitfield · 13 May 2026 · 9 min read

gray and white concrete building under blue sky during daytime

Medicinal Cannabis Access in Australia: Your Questions Answered

Roughly 350,000 Australians had been approved for medicinal cannabis as of late 2023, according to TGA approval data , a number that would have seemed implausible a decade ago. Yet the questions I still see circulating online suggest a lot of people are working from outdated or simply wrong information. So I've pulled together the most common ones here, sourced against the actual regulatory frameworks rather than forum speculation.

I'll admit this topic gives the librarian in me a small thrill. Between birdwatching trips out to Nudgee Beach and haunting the secondhand shelves at Bent Books on Fortitude Valley's Ann Street, I've spent more hours than I should tracking primary TGA documents on this one. Anyway. The questions.

Is medicinal cannabis legal in Australia?

Yes, under specific conditions. The Therapeutic Goods Administration (TGA) regulates medicinal cannabis as a therapeutic good. It sits across two schedules of the Poisons Standard: products containing cannabidiol (CBD) at prescription-only thresholds are Schedule 4 (Prescription Only), while products containing tetrahydrocannabinol (THC) above certain concentrations are Schedule 8 (Controlled Drug). Recreational use remains illegal across all Australian states and territories.

How does a patient actually access it?

There are two main pathways through the TGA.

The first is the Special Access Scheme (SAS), specifically Category B (SAS-B), which allows a registered medical practitioner to apply to the TGA on behalf of an individual patient for an unapproved therapeutic good. Most medicinal cannabis prescriptions flow through this pathway. The second is the Authorised Prescriber (AP) pathway, where a doctor applies to the TGA (with support from a Human Research Ethics Committee or a relevant specialist college) to become authorised to prescribe a specific product to a class of patients, without needing individual TGA approval each time.

Both pathways require a valid Australian prescription once TGA approval is granted. The prescribing doctor, not the patient, initiates the TGA process.

Does a product need to be on the ARTG?

Not necessarily, though some are. The Australian Register of Therapeutic Goods (ARTG) lists products that have been fully evaluated and approved for general supply. Most medicinal cannabis products currently accessed in Australia are not on the ARTG , they are unapproved goods accessed through SAS-B or the AP pathway. One notable exception is a pharmaceutical-grade cannabidiol oral solution that received full ARTG registration; it was the first cannabis-derived medicine to do so in Australia.

Can any doctor prescribe medicinal cannabis?

Any registered medical practitioner can apply through SAS-B. For Schedule 8 products, additional state and territory permits are generally required on top of the TGA approval , the rules vary by jurisdiction, so a doctor in Queensland operates under a different permit framework than one in Victoria or Western Australia. Nurse practitioners can prescribe in some circumstances but the rules are complex and jurisdiction-dependent. Pharmacists dispense; they do not prescribe.

What forms does medicinal cannabis come in?

Approved products currently on the Australian market include oils (taken sublingually or orally), capsules, dried flower (for vaporisation, not smoking), and topicals. The specific formulation matters for bioavailability; how much of the active compound reaches systemic circulation and how quickly. Oral products undergo first-pass metabolism in the liver, which meaningfully changes the absorption profile compared with inhaled or sublingual delivery. This is a pharmacology consideration that prescribers work through with patients.

What's the difference between CBD and THC products?

Chemically, CBD and THC are both cannabinoids derived from the cannabis plant, but they differ significantly in their interaction with the endocannabinoid system. THC binds directly and with high affinity to the CB1 receptor, which is concentrated in the central nervous system and accounts for its psychoactive effects. CBD has a much lower binding affinity at CB1 and acts through several other mechanisms. Regulatorily, that distinction maps onto Schedule 4 vs Schedule 8, products with meaningful THC concentrations attract tighter controls.

Some products are described as full-spectrum, meaning they contain a range of cannabinoids and terpenes from the plant. Others are broad-spectrum (multiple cannabinoids, THC removed) or isolate (a single purified cannabinoid). The entourage effect hypothesis proposes that these components interact, but it remains an active area of research rather than settled science.

Are there other cannabinoids in these products?

Yes. Depending on the formulation, products may contain minor cannabinoids including cannabigerol (CBG), CBN, CBC, and others. Their individual pharmacology and regulatory status varies. THCA and CBDA are the acidic precursor forms found in the raw plant; decarboxylation (heat) converts them to THC and CBD respectively. Novel or synthetic analogues like Delta-8-THC, HHC, and THCP are a different matter; their regulatory status in Australia is not straightforwardly equivalent to the plant-derived cannabinoids, and some are effectively Schedule 9 prohibited substances. I'd approach any product making claims about these compounds with scepticism until you've read the actual TGA scheduling instrument.

What manufacturing standards apply?

Medicinal cannabis products supplied in Australia must be manufactured to Good Manufacturing Practice (GMP) standards. The TGA requires either TGA-licensed manufacture in Australia or overseas manufacture under a comparable GMP framework. This is not a trivial standard, it covers everything from raw material sourcing and testing through to packaging, labelling, and batch records. It's one of the things that distinguishes regulated medicinal cannabis from unregulated products.

Is low-dose CBD available over the counter?

Since February 2021, the TGA has permitted pharmacists to supply certain low-dose CBD products (up to 150 mg/day) without a prescription, as a Schedule 3 (Pharmacist Only) medicine, but only for products specifically approved for that purpose and listed on the ARTG with a Schedule 3 indication. As of this writing, no product has actually achieved that ARTG listing for OTC supply. So the short version is: technically possible in principle, not practically available yet. This is worth watching.

Does medicinal cannabis show on a drug test?

This is one of the most practically important questions and the answer is: yes, THC and its metabolites will show on standard roadside and workplace drug tests, regardless of whether the patient holds a valid prescription. Roadside drug testing in Australia tests for the presence of THC, not impairment; a legal prescription does not provide a defence in most jurisdictions. Patients should discuss this explicitly with their prescribing doctor.

Can I travel interstate or overseas with medicinal cannabis?

Interstate travel with a Schedule 8 controlled drug requires compliance with the destination state's permit requirements, not just the originating state's. International travel is substantially more complex, most countries have no equivalent access framework, and carrying cannabis-derived products across international borders can constitute a serious criminal offence even where the patient holds an Australian prescription. The advice here is always to seek specific legal advice before attempting international travel with these products.

Are there any fully approved (ARTG-listed) products?

Yes, a small number. As noted above, one pharmaceutical-grade CBD oral solution holds full ARTG registration. There is also a plant-derived combination product containing both CBD and THC that has received registration for a specific indication. The ARTG public summary records are searchable on the TGA website and are, in my view, consistently underused by people trying to understand what's actually been evaluated versus what's being accessed through the unapproved-goods pathways.

What about the pharmacokinetics, does it matter how you take it?

Very much so. The pharmacokinetics of cannabinoids differ substantially by route of administration. Inhaled cannabinoids reach peak plasma concentration within minutes; oral products can take one to two hours, with significantly lower and more variable bioavailability due to first-pass hepatic metabolism. This has genuine clinical significance for prescribers deciding on formulation, and it's why the product form in an approval is specific; substituting one form for another isn't a neutral decision.

What does the research landscape look like?

Honestly, more limited than the public conversation implies. There is a reasonable body of clinical evidence for specific cannabinoid products in specific contexts, the published literature for certain pharmaceutical-grade products is more substantial than for whole-plant preparations. But the evidence base for many of the conditions for which patients seek access is still characterised by small sample sizes, short follow-up periods, and heterogeneous methodology. The TGA's own published guidance acknowledges this. I'd be cautious about any framing that presents the evidence as more settled than it is.

Where can I find reliable regulatory information?

The TGA's medicinal cannabis hub at tga.gov.au is the authoritative source for Australian regulatory status, guidance documents, and the ARTG. The Therapeutic Goods Act 1989 and the current Poisons Standard (the legislative instrument formally titled the Standard for the Uniform Scheduling of Medicines and Poisons) are both publicly accessible. State and territory health departments publish their own Schedule 8 permit requirements separately.

Sources

, Tom Whitfield, Health Librarian; References & Fact-Checking

Common questions

Do I need a referral to see a doctor about medicinal cannabis?: Not strictly — any registered medical practitioner can apply through the TGA's Special Access Scheme Category B on a patient's behalf, and some clinics operate as general practice. However, many GPs will refer to a specialist for complex cases, and some states require specialist involvement for certain Schedule 8 applications. Check with your GP as a first step.
Will my private health insurer cover medicinal cannabis?: Generally no. Most medicinal cannabis products in Australia are unapproved therapeutic goods accessed through SAS-B or the Authorised Prescriber pathway, and private health insurers do not typically cover unapproved medicines. Some pharmaceutical-grade products with full ARTG registration may be treated differently, but this varies by insurer and policy. Confirm directly with your fund.
Is medicinal cannabis on the Pharmaceutical Benefits Scheme (PBS)?: As of this writing, no medicinal cannabis product is listed on the PBS, meaning patients pay full out-of-pocket costs. This has been raised as an equity concern in parliamentary submissions and public health commentary, but no PBS listing has been approved. The TGA and PBS are separate processes — ARTG registration does not automatically trigger PBS listing.
What's the difference between the SAS and the Authorised Prescriber pathway?: Under the Special Access Scheme (SAS-B), a doctor applies to the TGA individually for each patient before prescribing an unapproved product. Under the Authorised Prescriber (AP) pathway, a doctor applies once — with ethics committee or specialist college endorsement — to be authorised to prescribe a specific product to a defined class of patients without needing individual TGA approval each time. AP status reduces administrative burden for prescribers who regularly treat patients in a particular area.
Can THC-containing products be prescribed for any condition, or only specific ones?: The SAS-B pathway does not restrict prescribing to a fixed list of approved indications — a doctor can apply for any patient for whom they consider it clinically appropriate. However, the TGA evaluates each application and may decline. Under the Authorised Prescriber pathway, the authorisation is tied to a specific patient population or condition. The clinical evidence base varies considerably across different conditions, and TGA guidance documents outline the strength of evidence the regulator has reviewed.